PALISADE BIO INC (PALI) Stock Price, Forecast & Analysis
USA - NASDAQ:PALI - US6963894026 - Common Stock
PALI Key Statistics, Chart & Performance
The current stock price of PALI is 1.77 USD. In the past month the price decreased by -4.32%. In the past year, price decreased by -29.76%.
PALI Latest News, Press Relases and Analysis
PALI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.14 | 386.36B | ||
| AMGN | AMGEN INC | 14.8 | 174.25B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 146.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.26 | 107.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 69.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 866.08 | 57.90B | ||
| INSM | INSMED INC | N/A | 40.57B | ||
| NTRA | NATERA INC | N/A | 28.36B | ||
| BIIB | BIOGEN INC | 9.33 | 22.91B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.89 | 14.88B |
Related stock screener links
About PALI
Company Profile
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 8 full-time employees. The company went IPO on 2006-12-20. The firm is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The firm is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. The company utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Company Info
PALISADE BIO INC
7750 El Camino Real, Suite 5200
Carlsbad CALIFORNIA 20876 US
CEO: Kenneth Carter
Employees: 8
Phone: 18587044900
PALISADE BIO INC / PALI FAQ
Can you describe the business of PALISADE BIO INC?
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 8 full-time employees. The company went IPO on 2006-12-20. The firm is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The firm is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. The company utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
What is the current price of PALI stock?
The current stock price of PALI is 1.77 USD. The price increased by 5.36% in the last trading session.
Does PALISADE BIO INC pay dividends?
PALI does not pay a dividend.
What is the ChartMill technical and fundamental rating of PALI stock?
PALI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists PALI stock?
PALI stock is listed on the Nasdaq exchange.
What is the market capitalization of PALI stock?
PALISADE BIO INC (PALI) has a market capitalization of 235.41M USD. This makes PALI a Micro Cap stock.
Can you provide the upcoming earnings date for PALISADE BIO INC?
PALISADE BIO INC (PALI) will report earnings on 2025-11-10.
PALI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PALI. When comparing the yearly performance of all stocks, PALI is one of the better performing stocks in the market, outperforming 91.6% of all stocks.
PALI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PALI. While PALI has a great health rating, there are worries on its profitability.
PALI Financial Highlights
Over the last trailing twelve months PALI reported a non-GAAP Earnings per Share(EPS) of -4.92. The EPS increased by 76.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.7% | ||
| ROE | -192.71% | ||
| Debt/Equity | 0 |
PALI Forecast & Estimates
9 analysts have analysed PALI and the average price target is 8.16 USD. This implies a price increase of 361.02% is expected in the next year compared to the current price of 1.77.